<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Med Sci Monit</journal-id><journal-id journal-id-type="iso-abbrev">Med. Sci. Monit</journal-id><journal-id journal-id-type="publisher-id">Medical Science Monitor</journal-id><journal-title-group><journal-title>Medical Science Monitor : International Medical Journal of Experimental and Clinical Research</journal-title></journal-title-group><issn pub-type="ppub">1234-1010</issn><issn pub-type="epub">1643-3750</issn><publisher><publisher-name>International Scientific Literature, Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7238808</article-id><article-id pub-id-type="pmid">32386284</article-id><article-id pub-id-type="doi">10.12659/MSM.924134</article-id><article-id pub-id-type="publisher-id">924134</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Research</subject></subj-group></article-categories><title-group><article-title>CircPSMC3 Suppresses Migration and Invasion of Non-Small Cell Lung Cancer Cells via miR-182-5p/NME2 Axis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Tao</given-names></name><xref ref-type="aff" rid="af1-medscimonit-26-e924134">1</xref><xref ref-type="author-notes" rid="fn2-medscimonit-26-e924134">B</xref><xref ref-type="author-notes" rid="fn3-medscimonit-26-e924134">C</xref><xref ref-type="author-notes" rid="fn4-medscimonit-26-e924134">D</xref><xref ref-type="author-notes" rid="fn5-medscimonit-26-e924134">E</xref><xref ref-type="author-notes" rid="fn6-medscimonit-26-e924134">F</xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Yejun</given-names></name><xref ref-type="aff" rid="af2-medscimonit-26-e924134">2</xref><xref ref-type="author-notes" rid="fn2-medscimonit-26-e924134">B</xref><xref ref-type="author-notes" rid="fn3-medscimonit-26-e924134">C</xref></contrib><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Shengcong</given-names></name><xref ref-type="aff" rid="af3-medscimonit-26-e924134">3</xref><xref ref-type="author-notes" rid="fn4-medscimonit-26-e924134">D</xref><xref ref-type="author-notes" rid="fn5-medscimonit-26-e924134">E</xref></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Lixiang</given-names></name><xref ref-type="aff" rid="af3-medscimonit-26-e924134">3</xref><xref ref-type="author-notes" rid="fn5-medscimonit-26-e924134">E</xref><xref ref-type="author-notes" rid="fn6-medscimonit-26-e924134">F</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Mao</surname><given-names>Zejun</given-names></name><xref ref-type="aff" rid="af3-medscimonit-26-e924134">3</xref><xref ref-type="author-notes" rid="fn1-medscimonit-26-e924134">A</xref><xref ref-type="author-notes" rid="fn7-medscimonit-26-e924134">G</xref></contrib></contrib-group><aff id="af1-medscimonit-26-e924134">
<label>1</label>Division of Pulmonary and Critical Care Medicine, Yinzhou People&#x02019;s Hospital, Ningbo, Zhejiang, P.R. China</aff><aff id="af2-medscimonit-26-e924134">
<label>2</label>Department of Stomatology, Zhuji People&#x02019;s Hospital, Zhuji, Zhejiang, P.R. China</aff><aff id="af3-medscimonit-26-e924134">
<label>3</label>Department of Cardiothoracic Surgery, Zhuji Hospital Affiliated to Shaoxing University, Zhuji, Zhejiang, P.R. China</aff><author-notes><corresp id="c1-medscimonit-26-e924134">Corresponding Author: Zejun Mao, e-mail: <email>zejunmao18@aliyun.com</email></corresp><fn id="fn1-medscimonit-26-e924134"><label>A</label><p>Study Design</p></fn><fn id="fn2-medscimonit-26-e924134"><label>B</label><p>Data Collection</p></fn><fn id="fn3-medscimonit-26-e924134"><label>C</label><p>Statistical Analysis</p></fn><fn id="fn4-medscimonit-26-e924134"><label>D</label><p>Data Interpretation</p></fn><fn id="fn5-medscimonit-26-e924134"><label>E</label><p>Manuscript Preparation</p></fn><fn id="fn6-medscimonit-26-e924134"><label>F</label><p>Literature Search</p></fn><fn id="fn7-medscimonit-26-e924134"><label>G</label><p>Funds Collection</p></fn></author-notes><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>09</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="epreprint"><day>30</day><month>4</month><year>2020</year></pub-date><volume>26</volume><fpage>e924134-1</fpage><lpage>e924134-9</lpage><history><date date-type="received"><day>09</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>16</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; Med Sci Monit, 2020</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0</ext-link>)</license-p></license></permissions><abstract><sec><title>Background</title><p>CircPSMC3 has been reported to play important roles in the occurrence and development of cancer. However, the role of circPSMC3 in NSCLC (non-small cell lung cancer) and the underlying mechanisms remain unclear.</p></sec><sec><title>Material/Methods</title><p>The expression of circPSMC3 in NSCLC tissues was measured through qRT-PCR (quantitative real-time polymerase chain reaction). The effect of circPSMC3 on the invasion and migration of NSCLC cell line H1299 was determined through transwell invasion assay and wound healing assay. Dual-luciferase reporter assay was performed for exploring the regulatory interaction between circPSMC3, miR-182-5p, and NME2.</p></sec><sec><title>Results</title><p>Compared with adjacent normal tissues, the expression of circPSMC3 in NSCLC tissues was decreased. Lower circPSMC3 expression was closely associated with lymph node metastasis and higher TNM stage in NSCLC patients. Biological function analysis suggested that circPSMC3 inhibits the invasion and migration of H1299 cells through upregulating the expression of NME2. Mechanistically, circPSMC3 sponges miR-182-5p to suppress the invasion and migration of NSCLC cells via upregulating NME2 expression.</p></sec><sec><title>Conclusions</title><p>CircPSMC3 inhibits the invasion and migration of NSCLC cells through the miR-182-5p/NME2 signaling pathway.</p></sec></abstract><kwd-group><title>MeSH Keywords</title><kwd>Carcinoma, Non-Small-Cell Lung</kwd><kwd>Genes, Tumor Suppressor</kwd><kwd>MicroRNAs</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Lung carcinoma is one of the most lethal malignancies [<xref rid="b1-medscimonit-26-e924134" ref-type="bibr">1</xref>]. Among all lung carcinoma cases, NSCLC (non-small cell lung cancer) accounts for about 85% [<xref rid="b2-medscimonit-26-e924134" ref-type="bibr">2</xref>]. Despite great progress in treatment of NSCLC, the 5-year survival rate of NSCLC remains less than 5% [<xref rid="b3-medscimonit-26-e924134" ref-type="bibr">3</xref>], primarily due to metastasis. Approximately 60% patients with NSCLC have had metastasis at their first diagnosis [<xref rid="b4-medscimonit-26-e924134" ref-type="bibr">4</xref>]. Notably, metastasis is considered to be inevitable during the progression of NSCLC [<xref rid="b5-medscimonit-26-e924134" ref-type="bibr">5</xref>]. Therefore, it is extremely urgent to investigate the genetic regulatory networks related to NSCLC metastases.</p><p>Circular RNAs (circRNAs) form covalently closed loops, and are a type of non-coding RNA, without polyadenylation tails and 5&#x02032; to 3&#x02032; polar [<xref rid="b6-medscimonit-26-e924134" ref-type="bibr">6</xref>]. circRNAs can be transcribed from both exons and introns of parent genes [<xref rid="b7-medscimonit-26-e924134" ref-type="bibr">7</xref>]. Recently, circRNAs have been reported to play important roles in the progression and development of cancer [<xref rid="b8-medscimonit-26-e924134" ref-type="bibr">8</xref>]. In fact, dysregulation of circRNAs has already been found in many types of cancers [<xref rid="b9-medscimonit-26-e924134" ref-type="bibr">9</xref>]. Emerging evidence shows that circRNAs can sequester and sponge miRNAs to regulate gene transcription to participate in cancer development [<xref rid="b10-medscimonit-26-e924134" ref-type="bibr">10</xref>]. For instance, circPSMC3 levels are low in gastric cancer and inhibit the metastasis and proliferation of gastric cancer via sponging miR-296-5p to upregulate the expression of PTEN [<xref rid="b11-medscimonit-26-e924134" ref-type="bibr">11</xref>]. circPSMC3 suppresses the migration and invasion of hepatocellular carcinoma cells through upregulating RBM5 [<xref rid="b12-medscimonit-26-e924134" ref-type="bibr">12</xref>]. Moreover, circPSMC3 can induce cell apoptosis and suppress cell proliferation among nasopharyngeal carcinoma through downregulating the expression of ROCK1 [<xref rid="b13-medscimonit-26-e924134" ref-type="bibr">13</xref>]. However, the roles of circPSMC3 in the occurrence and progression of NSCLC remain unclear.</p><p>In the present study we investigated the role of circPSMC3 in lung cancer, and assessed the relationship between the circPSMC3 expression and TNM stage and lymph node metastasis in NSCLC patients. We further explored the molecular mechanisms of circPSMC3 in suppressing lung cancer, and analyzed the role of circPSMC3 in upregulating NME2 expression, which is inhibited by miR-182-5p in lung cancer.</p></sec><sec sec-type="materials|methods"><title>Material and Methods</title><sec><title>NSCLC tissues</title><p>The Research Ethic Committee of Zhuji People&#x02019;s Hospital (Zhuji, Zhejiang, P.R. China) approved the present study (No. 20170128), in which 103 pairs of NSCLC and normal tissues were collected from the Department of Cardiothoracic Surgery, Zhuji People&#x02019;s Hospital. All patients gave written informed consent.</p></sec><sec><title>Cell culture</title><p>GLC-82 cells were obtained from the Chinese Academy of Sciences (Shanghai, China). The cell lines H1299 (ATCC<sup>&#x000ae;</sup> CRL-5803), A549 (ATCC<sup>&#x000ae;</sup> CRM-CCL-185), H157 (ATCC<sup>&#x000ae;</sup> CRL-5802), and H358 (ATCC<sup>&#x000ae;</sup> CRL-5807) were purchased from ATCC<sup>&#x000ae;</sup> (Maryland, USA). The culture conditions of NSCLC cells lines were: DMEM (HyClone), 10% FBS (fetal bovine serum, Gibco), 37&#x000b0;C, and 5% CO<sub>2</sub>.</p></sec><sec><title>RT-qPCR</title><p>RNAs extraction and RT-qPCR were conducted as described elsewhere [<xref rid="b1-medscimonit-26-e924134" ref-type="bibr">1</xref>]. TRIzol reagent from TaKaRa (Japan) was used for extraction of RNAs. RT-qPCR was performed using SYBR Premix Ex Taq II (Takara, Japan). Experiments were conducted according to the manufacturer&#x02019;s instructions. The primers of circPSMC3 were:</p><list list-type="simple"><list-item><p>Reverse: 5&#x02032;-GTGTTGGGCTGGAAGCCATC-3&#x02032;;</p><p>Forward: 5&#x02032;-GTTTAGGGTCCCTGCCCTTTG-3&#x02032;.</p></list-item></list><p>The primers of circPSMC3 and GAPDH were from Sangon Biotech (Shanghai, China).</p></sec><sec><title>Wound healing assay</title><p>H1299 and H157 cells were seeded in 6-well plates. Marker was conducted on the back of 6-well plates, with a 0.5~1-cm horizontal line across the 6-well plate. When cell confluence reached 80%, a scratch was made using 10-&#x003bc;L pipette tips, and scratched the horizontal line for annotating the image and measuring the distance. Then, the linear wound was photographed at 0 h and 48 h using microscopy. Image J software was used to measure the width of the scratch. Experiments were repeated 3 times.</p></sec><sec><title>Transwell invasion assay</title><p>H1299 and H157 cells (5&#x000d7;10<sup>4</sup>) were seeded in upper chambers with 2% FBS medium, and 10% FBS medium was added to the lower chamber (24-well plates). Hanging cell culture inserts, with 8 &#x003bc;m pore size (PIEP12R48, Millipore), were used for the upper chambers in 24-well plates. After 24 h, cells that transmigrated through the upper chamber were fixed with 4% paraformaldehyde and stained with crystal violet. Representative images were photographed at 24 h using microscopy.</p></sec><sec sec-type="methods"><title>Western blot analysis</title><p>H1299 and H157 cells were collected at indicated times. Then, extracted proteins were separated using SDS-PAGE. Separated proteins were transferred onto PVDF membrane (Millipore, USA), which were then cultured with 5% non-fat milk in TBST for 1 h. The protein of interest was incubated with NME2 primary antibody (Abcam, USA) at 4&#x000b0;C for 12 h, and continued to be incubated with secondary antibodies (HRP-labeled secondary antibodies, Sigma, USA) for 2 h at 37&#x000b0;C. The reaction was visualized using ECL (Millipore, USA).</p></sec><sec><title>Dual-luciferase reporter assay</title><p>H1299 cells were cultured in 96-well plates. When H1299 cell confluence reached 40%, reporter plasmids and miR-182-5p-mimic were simultaneously transfected into H1299 cells with Lipofectamine 2000. After 48 h, based on Luciferase<sup>&#x000ae;</sup> Reporter Assay protocol (Promega), luciferase experiments were carried out to measure the Renilla and firefly luciferase activities. Then, the ratio of the Renilla/firefly luciferase activities was further calculated.</p></sec><sec sec-type="methods"><title>Statistical analysis</title><p>Data analysis was performed using GraphPad Prism 6. The unpaired <italic>t</italic> test and Pearson correlation analysis were used, with <italic>P</italic>&#x0003c;0.05 set as the level of statistical significance.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>CircPSMC3 expression was decreased in NSCLC cells and was associated with TNM stage and lymph node metastasis</title><p>circPSMC3 expression is reported to be reduced in gastric cancer [<xref rid="b11-medscimonit-26-e924134" ref-type="bibr">11</xref>], but circPSMC3 expression in NSCLC tissues is unknown. Therefore, to assess circPSMC3 expression in NSCLC, qRT-PCR was carried out to assess its expression in 103 pairs of NSCLC tissues and corresponding normal tissues. As shown in <xref ref-type="fig" rid="f1-medscimonit-26-e924134">Figure 1A</xref>, circPSMC3 expression was lower in NSCLC tissues than in adjacent normal tissues. Moreover, our results showed that circPSMC3 expression was obviously downregulated among patients with stage III/IV compared to those with stage I/II (<xref ref-type="fig" rid="f1-medscimonit-26-e924134">Figure 1B</xref>). In addition, lower circPSMC3 expression was closely associated with lymph node metastasis and higher TNM stage in NSCLC patients (<xref rid="t1-medscimonit-26-e924134" ref-type="table">Table 1</xref>). These results indicate that circPSMC3 expression is decreased in NSCLC and is associated with metastasis of NSCLC.</p></sec><sec><title>CircPSMC3 suppressed the invasion and migration of NSCLC cells</title><p>To investigate the roles of circPSMC3 in the invasion and migration of NSCLC cells, the expression of circPSMC3 was assessed in several NSCLC cell lines (GLC-82, H1299, A549, H157, and H358) via qRT-PCR. As shown in <xref ref-type="fig" rid="f2-medscimonit-26-e924134">Figure 2A</xref>, there was higher circPSMC3 expression in H1299 than in the other 4 NSCLC cell lines. Therefore, H1299 cells were selected to be transfected with si-circPSMC3 for further function analysis. H157 cells were assessed for circPSMC3 overexpression. Si-circPSMC3 transection and circPSMC3 overexpression efficiency were measured via qRT-PCR (<xref ref-type="fig" rid="f2-medscimonit-26-e924134">Figure 2B, 2C</xref>). Silenced circPSMC3 promoted the invasion and migration of H1299 cells, and the opposite was found in H157 cells (<xref ref-type="fig" rid="f2-medscimonit-26-e924134">Figure 2D&#x02013;2I</xref>). These observations indicate that circPSMC3 inhibits the invasion and migration of NSCLC cells.</p></sec><sec><title>CircPSMC3 inhibited the invasion and migration of NSCLC cells by regulating NME2</title><p>NME was the first suppressor gene reported to be associated with metastasis. NME overexpression can merely inhibit tumor metastasis without affecting primary tumor size [<xref rid="b14-medscimonit-26-e924134" ref-type="bibr">14</xref>]. NME2 (nucleoside diphosphate kinase 2), among 10 genes of the NME family, is the most studied in metastasis. In lung cancer, NME2 expression is negatively correlated with tumor stage [<xref rid="b15-medscimonit-26-e924134" ref-type="bibr">15</xref>,<xref rid="b16-medscimonit-26-e924134" ref-type="bibr">16</xref>]. To investigate the effect of circPSMC3 on NME2 expression, the NME2 mRNA and protein expression was detected in H1299 cells transfected with si-circPSMC3, as well as H157 cells with circPSMC3 overexpression. As shown in <xref ref-type="fig" rid="f3-medscimonit-26-e924134">Figure 3A&#x02013;3C</xref>, silenced circPSMC3 inhibited NME2 expression at protein and mRNA levels. To further explore the roles of NME2 in the invasion and migration of NSCLC cells, transwell invasion assay and wound healing assay were conducted in H1299 and H157 cells transfected with si-NC and si-NME2. We showed that silencing of NME2 blocked the inhibitory effects of circPSMC3 on the invasion and migration of H1299 cells, and the opposite was found in H157 cells (<xref ref-type="fig" rid="f3-medscimonit-26-e924134">Figure 3D&#x02013;3I</xref>). In conclusion, circPSMC3 can inhibit the invasion and migration of NSCLC cells via upregulating NME2.</p></sec><sec><title>NME2 is a target gene of miR-182-5p</title><p>According to the predication of TargetScanHuman software (<ext-link ext-link-type="uri" xlink:href="http://www.targetscan.org/">http://www.targetscan.org/</ext-link>), there is a binding site of miR-182-5p in NME2 (<xref ref-type="fig" rid="f4-medscimonit-26-e924134">Figure 4A</xref>). Then, the relative luciferase activity was measured using reporter plasmids cloned with miR-182-5p binding sequences in NME2 3&#x02032;-UTR wildtype and mutant counterparts. As shown in <xref ref-type="fig" rid="f4-medscimonit-26-e924134">Figure 4B</xref>, the relative luciferase activity was obviously decreased in H1299 cells transfected with miR-182-5p-mimic, and the opposite was found in H157 cells transfected with miR-182-5p inhibitor. Moreover, miR-182-5p remarkably downregulated NME2 expression in H1299 and H157 cells (<xref ref-type="fig" rid="f4-medscimonit-26-e924134">Figure 4C</xref>). To explore the relationship between NME2 and miR-182-5p, Pearson correlation analysis was performed. The results showed that there was negative relationship between NME2 and miR-182-5p in NSCLC tissues (<xref ref-type="fig" rid="f4-medscimonit-26-e924134">Figure 4D</xref>). Taken together, these results suggest that NME2 is a target gene of miR-182-5p.</p></sec><sec><title>CircPSMC3 can sponge miR-182-5p in non-small cell lung cancer cells</title><p>To identify the molecular mechanisms related to circPSMC3-induced NME2 expression, a binding site of miR-182-5p in circPSMC3 was predicted using Starbase software (<ext-link ext-link-type="uri" xlink:href="http://www.targetscan.org/">http://www.targetscan.org/</ext-link>) (<xref ref-type="fig" rid="f5-medscimonit-26-e924134">Figure 5A</xref>). Then, the relative luciferase activity was analyzed using reporter plasmids cloned with miR-182-5p binding sequences in circPSMC3 wildtype and mutant counterparts. As shown in <xref ref-type="fig" rid="f5-medscimonit-26-e924134">Figure 5B</xref>, there was distinctly lower relative luciferase activity in H1299 cells transfected with miR-182-5p-mimic compared to H157 cells transfected with miR-182-5p inhibitor. Furthermore, miR-182-5p expression was much higher in the si-circPSMC3 group than in the si-NC group in H1299 cells, and the opposite was found in H157 cells. (<xref ref-type="fig" rid="f5-medscimonit-26-e924134">Figure 5C</xref>). In addition, Pearson correlation analysis showed a negative relationship between circPSMC3 and miR-182-5p in NSCLC tissues (<xref ref-type="fig" rid="f5-medscimonit-26-e924134">Figure 5D</xref>). These results suggest that circPSMC3 sponges miR-182-5p in NSCLC.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Despite improvement in understanding the biology of NSCLC, metastasis remains an important challenge for treatment strategies. Therefore, exploring the regulatory mechanism of metastasis in non-small cell lung cancer is vital for developing effective treatment strategies. In the present study, we found that circPSMC3 suppressed the invasion and migration of NSCLC cells via the miR-182-5p/NME2 signaling pathway.</p><p>CircRNAs are geared to endogenous non-coding RNAs, and increasing evidence has demonstrated that circRNAs play a crucial role in cancer [<xref rid="b17-medscimonit-26-e924134" ref-type="bibr">17</xref>&#x02013;<xref rid="b19-medscimonit-26-e924134" ref-type="bibr">19</xref>]. For example, PVT1 can sponge miR425 to promote the proliferation of gastric cancer cells [<xref rid="b20-medscimonit-26-e924134" ref-type="bibr">20</xref>]. Hsa_circ_0005075 also has discrepant expression in hepatocellular cancer, and is correlated with tumor size [<xref rid="b21-medscimonit-26-e924134" ref-type="bibr">21</xref>]. In lung cancer, circ-ITCH is overexpressed, and can inhibit the Wnt/&#x003b2;-catenin signaling pathway through serving as miR-7 and miR-214 sponges, which participate in the regulation of metastasis [<xref rid="b22-medscimonit-26-e924134" ref-type="bibr">22</xref>]. Moreover, circRNA100876 expression is increased in NSCLC, and higher circRNA100876 level is closely related to the metastasis of lymph nodes and tumor stage [<xref rid="b23-medscimonit-26-e924134" ref-type="bibr">23</xref>]. CircPSMC3 inhibits the metastasis and proliferation of gastric cancer through sponging miR-296-5p via serving as a competitive endogenous RNA [<xref rid="b11-medscimonit-26-e924134" ref-type="bibr">11</xref>]. In addition, circPSMC3 inhibits hepatocellular carcinoma migration and invasion by upregulating RBM5 [<xref rid="b12-medscimonit-26-e924134" ref-type="bibr">12</xref>]. Similar to previous findings, we demonstrated that circPSMC3 was reduced in NSCLC, and targeted miR-182-5p to suppress the metastasis of NSCLC. The function of miR-182-5p in cancer has been reported early. miR-182-5p can enhance the invasion, migration, viability, and mitosis of human gastric cells via suppressing RAB27A [<xref rid="b24-medscimonit-26-e924134" ref-type="bibr">24</xref>]. Furthermore, miR-182-5p enhances the motility and invasive ability of hepatocellular cancer cells [<xref rid="b25-medscimonit-26-e924134" ref-type="bibr">25</xref>]. These previous results are consistent with our present findings.</p><p>The NME gene was the first metastasis suppressor to be reported. Some studies have confirmed that NME2 can suppress metastasis through regulating cell adhesion factors, such as vinculin [<xref rid="b26-medscimonit-26-e924134" ref-type="bibr">26</xref>]. Others found that NME2 can repress telomerase activity for MDM2 activity inhibition, causing decreased cell motility [<xref rid="b16-medscimonit-26-e924134" ref-type="bibr">16</xref>]. In gastric cancer, NME2 can repress metastasis through reducing cell migration and invasion ability [<xref rid="b27-medscimonit-26-e924134" ref-type="bibr">27</xref>]. Moreover, NME2 expression is negatively correlated with advanced/metastatic phase in multiple cancers, such as breast cancer and melanoma [<xref rid="b28-medscimonit-26-e924134" ref-type="bibr">28</xref>]. To assess the effect of circPSMC3 on NME2 expression, the protein and mRNA expression of NME2 were detected among H1299 cells transfected with si-circPSMC3. Our results showed that circPSMC3 inhibits the invasion and migration of NSCLC cells via upregulating NME2. In addition, NME2 expression was reported to be regulated by miRNAs. NME2 is directly targeted by miR-645, and is involved in modulating cell migration [<xref rid="b29-medscimonit-26-e924134" ref-type="bibr">29</xref>], while CARMA3 enhances the motility of lung cancer cells through reducing the expression of NME2 via the NF-&#x003ba;B/miR-182 axis [<xref rid="b29-medscimonit-26-e924134" ref-type="bibr">29</xref>]. In the present study, we used TargetScanHuman software to predict the existence of a binding site of miR-182-5p in NME2. The results of luciferase reporter assay showed that NME2 is a target gene of miR-182-5p in NSCLC.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Our results indicated that circPSMC3 expression was decreased in NSCLC tissues compared with adjacent normal tissues. Lower circPSMC3 expression was closely associated with lymph node metastasis and higher TNM stage in NSCLC patients. Most important, the present data shows that circPSMC3 inhibits the invasion and migration of NSCLC cells via the miR-182-5p/NME2 axis.</p></sec></body><back><fn-group><fn id="fn8-medscimonit-26-e924134" fn-type="COI-statement"><p><bold>Conflict of interests</bold></p><p>None.</p></fn><fn id="fn9-medscimonit-26-e924134"><p><bold>Source of support:</bold> Departmental sources</p></fn></fn-group><ref-list><title>References</title><ref id="b1-medscimonit-26-e924134"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name></person-group><article-title>PVT1 promotes angiogenesis by regulating miR-29c/vascular endothelial growth factor (VEGF) signaling pathway in non-small-cell lung cancer (NSCLC)</article-title><source>Med Sci Monit</source><year>2019</year><volume>25</volume><fpage>5418</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">31326971</pub-id></element-citation></ref><ref id="b2-medscimonit-26-e924134"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herbst</surname><given-names>RS</given-names></name><name><surname>Heymach</surname><given-names>JV</given-names></name><name><surname>Lippman</surname><given-names>SM</given-names></name></person-group><article-title>Lung cancer</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>1367</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">18815398</pub-id></element-citation></ref><ref id="b3-medscimonit-26-e924134"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Jin</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>AIM2 promotes non-small-cell lung cancer cell growth through inflammasome-dependent pathway</article-title><source>J Cell Physiol</source><year>2019</year><volume>234</volume><fpage>20161</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">30953357</pub-id></element-citation></ref><ref id="b4-medscimonit-26-e924134"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgensztern</surname><given-names>D</given-names></name><name><surname>Ng</surname><given-names>SH</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Govindan</surname><given-names>R</given-names></name></person-group><article-title>Trends in stage distribution for patients with non-small cell lung cancer: A National Cancer Database survey</article-title><source>J Thorac Oncol</source><year>2010</year><volume>5</volume><fpage>29</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">19952801</pub-id></element-citation></ref><ref id="b5-medscimonit-26-e924134"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Luan</surname><given-names>XR</given-names></name></person-group><article-title>miR-147a suppresses the metastasis of non-small-cell lung cancer by targeting CCL5</article-title><source>J Int Med Res</source><year>2019</year><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="b6-medscimonit-26-e924134"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilusz</surname><given-names>JE</given-names></name><name><surname>Sharp</surname><given-names>PA</given-names></name></person-group><article-title>Molecular biology. A circuitous route to noncoding RNA</article-title><source>Science</source><year>2013</year><volume>340</volume><fpage>440</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">23620042</pub-id></element-citation></ref><ref id="b7-medscimonit-26-e924134"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeck</surname><given-names>WR</given-names></name><name><surname>Sharpless</surname><given-names>NE</given-names></name></person-group><article-title>Detecting and characterizing circular RNAs</article-title><source>Nat Biotechnol</source><year>2014</year><volume>32</volume><fpage>453</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">24811520</pub-id></element-citation></ref><ref id="b8-medscimonit-26-e924134"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Rong</surname><given-names>D</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name></person-group><article-title>circPSMC3: ceRNA and tumor suppressor</article-title><source>Oncotarget</source><year>2019</year><volume>10</volume><fpage>3433</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">31191816</pub-id></element-citation></ref><ref id="b9-medscimonit-26-e924134"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>N</given-names></name><etal/></person-group><article-title>Recent progress in circular RNAs in human cancers</article-title><source>Cancer Lett</source><year>2017</year><volume>404</volume><fpage>8</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">28705773</pub-id></element-citation></ref><ref id="b10-medscimonit-26-e924134"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name><etal/></person-group><article-title>Circular RNAs in cancer: Novel insights into origins, properties, functions and implications</article-title><source>Am J Cancer Res</source><year>2015</year><volume>5</volume><fpage>472</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">25973291</pub-id></element-citation></ref><ref id="b11-medscimonit-26-e924134"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rong</surname><given-names>D</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><etal/></person-group><article-title>CircPSMC3 suppresses the proliferation and metastasis of gastric cancer by acting as a competitive endogenous RNA through sponging miR-296-5p</article-title><source>Mol Cancer</source><year>2019</year><volume>18</volume><fpage>25</fpage><pub-id pub-id-type="pmid">30777076</pub-id></element-citation></ref><ref id="b12-medscimonit-26-e924134"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>F</given-names></name><etal/></person-group><article-title>Circular circPSMC3 inhibits hepatocellular carcinoma migration and invasion by upregulating RBM5</article-title><source>Minerva Med</source><year>2019</year><comment>[Epub ahead of print]</comment></element-citation></ref><ref id="b13-medscimonit-26-e924134"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>DQ</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>CircPSMC3 inhibits cell proliferation and induces cell apoptosis in nasopharyngeal carcinoma by downregulating ROCK1</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2020</year><volume>24</volume><fpage>1219</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">32096151</pub-id></element-citation></ref><ref id="b14-medscimonit-26-e924134"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salerno</surname><given-names>M</given-names></name><name><surname>Ouatas</surname><given-names>T</given-names></name><name><surname>Palmieri</surname><given-names>D</given-names></name><name><surname>Steeg</surname><given-names>PS</given-names></name></person-group><article-title>Inhibition of signal transduction by the nm23 metastasis suppressor: possible mechanisms</article-title><source>Clin Exp Metastasis</source><year>2003</year><volume>20</volume><fpage>3</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">12650601</pub-id></element-citation></ref><ref id="b15-medscimonit-26-e924134"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramaniam</surname><given-names>S</given-names></name><name><surname>Thakur</surname><given-names>RK</given-names></name><name><surname>Yadav</surname><given-names>VK</given-names></name><etal/></person-group><article-title>Lung cancer biomarkers: State of the art</article-title><source>J Carcinog</source><year>2013</year><volume>12</volume><fpage>3</fpage><pub-id pub-id-type="pmid">23599685</pub-id></element-citation></ref><ref id="b16-medscimonit-26-e924134"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>YW</given-names></name><name><surname>Chiu</surname><given-names>CF</given-names></name><name><surname>Lee</surname><given-names>KY</given-names></name><etal/></person-group><article-title>CARMA3 represses metastasis suppressor NME2 to promote lung cancer stemness and metastasis</article-title><source>Am J Respir Crit Care Med</source><year>2015</year><volume>192</volume><fpage>64</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">25906011</pub-id></element-citation></ref><ref id="b17-medscimonit-26-e924134"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kristensen</surname><given-names>LS</given-names></name><name><surname>Andersen</surname><given-names>MS</given-names></name><name><surname>Stagsted</surname><given-names>LVW</given-names></name><etal/></person-group><article-title>The biogenesis, biology and characterization of circular RNAs</article-title><source>Nat Rev Genet</source><year>2019</year><volume>20</volume><fpage>675</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">31395983</pub-id></element-citation></ref><ref id="b18-medscimonit-26-e924134"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>G</given-names></name><name><surname>Ning</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Translation and functional roles of circular RNAs in human cancer</article-title><source>Mol Cancer</source><year>2020</year><volume>19</volume><fpage>30</fpage><pub-id pub-id-type="pmid">32059672</pub-id></element-citation></ref><ref id="b19-medscimonit-26-e924134"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><etal/></person-group><article-title>Circular RNAs in cancer: Emerging functions in hallmarks, stemness, resistance and roles as potential biomarkers</article-title><source>Mol Cancer</source><year>2019</year><volume>18</volume><fpage>90</fpage><pub-id pub-id-type="pmid">30999909</pub-id></element-citation></ref><ref id="b20-medscimonit-26-e924134"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer</article-title><source>Cancer Lett</source><year>2017</year><volume>388</volume><fpage>208</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">27986464</pub-id></element-citation></ref><ref id="b21-medscimonit-26-e924134"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Comprehensive circular RNA profiling reveals that hsa_circ_0005075, a new circular RNA biomarker, is involved in hepatocellular carcinoma development</article-title><source>Medicine (Baltimore)</source><year>2016</year><volume>95</volume><fpage>e3811</fpage><pub-id pub-id-type="pmid">27258521</pub-id></element-citation></ref><ref id="b22-medscimonit-26-e924134"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>K</given-names></name><etal/></person-group><article-title>Circular RNA-ITCH suppresses lung cancer proliferation via inhibiting the Wnt/beta-Catenin pathway</article-title><source>Biomed Res Int</source><year>2016</year><volume>2016</volume><comment>1579490</comment></element-citation></ref><ref id="b23-medscimonit-26-e924134"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>JT</given-names></name><name><surname>Zhao</surname><given-names>SH</given-names></name><name><surname>Liu</surname><given-names>QP</given-names></name><etal/></person-group><article-title>Over-expression of CircRNA_100876 in non-small cell lung cancer and its prognostic value</article-title><source>Pathol Res Pract</source><year>2017</year><volume>213</volume><fpage>453</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">28343871</pub-id></element-citation></ref><ref id="b24-medscimonit-26-e924134"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Shan</surname><given-names>Z</given-names></name><etal/></person-group><article-title>miR-182-5p improves the viability, mitosis, migration, and invasion ability of human gastric cancer cells by down-regulating RAB27A</article-title><source>Biosci Rep</source><year>2017</year><volume>37</volume><issue>3</issue><comment>pii: BSR20170136</comment></element-citation></ref><ref id="b25-medscimonit-26-e924134"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>MQ</given-names></name><name><surname>You</surname><given-names>AB</given-names></name><name><surname>Zhu</surname><given-names>XD</given-names></name><etal/></person-group><article-title>miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a</article-title><source>J Hematol Oncol</source><year>2018</year><volume>11</volume><fpage>12</fpage><pub-id pub-id-type="pmid">29361949</pub-id></element-citation></ref><ref id="b26-medscimonit-26-e924134"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>NME2 is a master suppressor of apoptosis in gastric cancer cells via transcriptional regulation of miR-100 and other survival factors</article-title><source>Mol Cancer Res</source><year>2019</year><volume>18</volume><fpage>287</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">31694930</pub-id></element-citation></ref><ref id="b27-medscimonit-26-e924134"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>YF</given-names></name><name><surname>Yang</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><etal/></person-group><article-title>NME2 reduces proliferation, migration and invasion of gastric cancer cells to limit metastasis</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><fpage>e0115968</fpage><pub-id pub-id-type="pmid">25700270</pub-id></element-citation></ref><ref id="b28-medscimonit-26-e924134"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saha</surname><given-names>D</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Hussain</surname><given-names>T</given-names></name><etal/></person-group><article-title>Epigenetic suppression of human telomerase (hTERT) is mediated by the metastasis suppressor NME2 in a G-quadruplex-dependent fashion</article-title><source>J Biol Chem</source><year>2017</year><volume>292</volume><fpage>15205</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">28717007</pub-id></element-citation></ref><ref id="b29-medscimonit-26-e924134"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>GJ</given-names></name><name><surname>Zhang</surname><given-names>SJ</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>MicroRNA-645 promotes metastasis of osteosarcoma via targeting tumor suppressor NM23 nucleoside diphosphate kinase 2</article-title><source>Clin Exp Pharmacol Physiol</source><year>2018</year><volume>45</volume><fpage>1317</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">29956840</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-medscimonit-26-e924134" position="float"><label>Figure 1</label><caption><p>CircPSMC3 expression was decreased in NSCLC. (<bold>A</bold>) The expression of circPSMC3 was assessed in NSCLC tissues and corresponding normal tissues using qRT-PCR. n=103. (<bold>B</bold>) The expression of circPSMC3 was analyzed in patients with stage I/II (n=39) and with stage III/IV (n=64).</p></caption><graphic xlink:href="medscimonit-26-e924134-g001"/></fig><fig id="f2-medscimonit-26-e924134" position="float"><label>Figure 2</label><caption><p>CircPSMC3 inhibits the invasion and migration of NSCLC cells. (<bold>A</bold>) The expression of circPSMC3 was assessed among several NSCLC cell lines by qRT-PCR. ** <italic>P</italic>&#x0003c;0.01. (<bold>B</bold>) The expression of circPSMC3 in H1299 cells transfected with si-circPSMC3 or si-NC was measured via qRT-PCR. ** <italic>P</italic>&#x0003c;0.01. (<bold>C</bold>) The expression of circPSMC3 in H157 cells transfected with circPSMC3 or vector was measured via qRT-PCR. ** <italic>P</italic>&#x0003c;0.01. (<bold>D&#x02013;I</bold>), Si-circPSMC3 were transfected into H1299 cells and CircPSMC3 was transfected into H157 cells. The cell migration ability was observed by wound healing assay (<bold>D&#x02013;F</bold>). ** <italic>P</italic>&#x0003c;0.01. Cellular invasion ability was tested by transwell invasion assay (<bold>G&#x02013;I</bold>). ** <italic>P</italic>&#x0003c;0.01.</p></caption><graphic xlink:href="medscimonit-26-e924134-g002"/></fig><fig id="f3-medscimonit-26-e924134" position="float"><label>Figure 3</label><caption><p>CircPSMC3 can inhibit the migration and invasion of NSCLC cells by regulating NME2. (<bold>A&#x02013;C</bold>) Si-circPSMC3 was transfected into H1299 cells. CircPSMC3 was transfected into H157 cells. RT-qPCR (<bold>A, B</bold>) and Western blot (<bold>C</bold>) were used to measure NME2 protein and mRNA expression. *** <italic>P</italic>&#x0003c;0.001. (<bold>D&#x02013;I</bold>) Si-NME2 or si-Control was transfected into H1299 and H157 cells transfected with si-NC. Cell migration ability was assessed via wound healing assay (<bold>D&#x02013;F</bold>). Cellular invasion ability was tested through transwell invasion assay (<bold>G&#x02013;I</bold>). ** <italic>P</italic>&#x0003c;0.01; * <italic>P</italic>&#x0003c;0.05.</p></caption><graphic xlink:href="medscimonit-26-e924134-g003"/></fig><fig id="f4-medscimonit-26-e924134" position="float"><label>Figure 4</label><caption><p>NME2 is a target gene of miR-182-5p. (<bold>A</bold>) The predicted binding site of miR-182-5p in NME2. (<bold>B, C</bold>) miR-182-5p-mimic was transfected into H1299 cells. miR-182-5p inhibitor was transfected into H157 cells. The relative luciferase activity was measured (<bold>B</bold>). RT-qPCR was used to detect NME2 mRNA expression (<bold>C</bold>). *** <italic>P</italic>&#x0003c;0.001. (<bold>D</bold>) The relationship between NME2 and miR-182-5p in NSCLC tissues was explored using Pearson correlation analysis.</p></caption><graphic xlink:href="medscimonit-26-e924134-g004"/></fig><fig id="f5-medscimonit-26-e924134" position="float"><label>Figure 5</label><caption><p>CircPSMC3 can sponge miR-182-5p in NSCLC cells. (<bold>A</bold>) The predicted binding site of miR-182-5p in circPSMC3. (<bold>B</bold>) miR-182-5p-mimic was transfected into H1299 cells. miR-182-5p inhibitor were transfected into H157 cells. The relative luciferase activity was detected. *** <italic>P</italic>&#x0003c;0.001. (<bold>C</bold>) Si-circPSMC3 was transfected into H1299 cells. CircPSMC3 was transfected into H157 cells. RT-qPCR was used to detect miR-182-5p expression. *** <italic>P</italic>&#x0003c;0.001. (<bold>D</bold>) Pearson correlation analysis was used to explore the relationship between circPSMC3 and miR-182-5p in NSCLC tissues.</p></caption><graphic xlink:href="medscimonit-26-e924134-g005"/></fig><table-wrap id="t1-medscimonit-26-e924134" position="float"><label>Table 1</label><caption><p>Relationship between circPSMC3 level and clinicopathologic characteristics in patients with NSCLC.</p></caption><table frame="hsides" rules="rows"><thead><tr><th valign="middle" rowspan="2" align="center" colspan="1">Clinicopathological characteristics</th><th valign="middle" rowspan="2" align="center" colspan="1">Number</th><th colspan="2" valign="middle" align="center" rowspan="1">circPSMC3 expression</th><th valign="middle" rowspan="2" align="center" colspan="1"><italic>P</italic> value</th></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1">Low</th><th valign="middle" align="center" rowspan="1" colspan="1">High</th></tr></thead><tbody><tr><td colspan="5" valign="middle" align="left" rowspan="1">Age (years)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;&#x02265;60</td><td valign="middle" align="center" rowspan="1" colspan="1">59</td><td valign="middle" align="center" rowspan="1" colspan="1">38</td><td valign="middle" align="center" rowspan="1" colspan="1">21</td><td valign="middle" rowspan="2" align="center" colspan="1">0.874</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;&#x0003c;60</td><td valign="middle" align="center" rowspan="1" colspan="1">44</td><td valign="middle" align="center" rowspan="1" colspan="1">29</td><td valign="middle" align="center" rowspan="1" colspan="1">15</td></tr><tr><td colspan="5" valign="middle" align="left" rowspan="1">Gender</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Male</td><td valign="middle" align="center" rowspan="1" colspan="1">65</td><td valign="middle" align="center" rowspan="1" colspan="1">45</td><td valign="middle" align="center" rowspan="1" colspan="1">20</td><td valign="middle" rowspan="2" align="center" colspan="1">0.244</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Female</td><td valign="middle" align="center" rowspan="1" colspan="1">38</td><td valign="middle" align="center" rowspan="1" colspan="1">22</td><td valign="middle" align="center" rowspan="1" colspan="1">16</td></tr><tr><td colspan="5" valign="middle" align="left" rowspan="1">Tumor size (cm)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;&#x02265;3</td><td valign="middle" align="center" rowspan="1" colspan="1">69</td><td valign="middle" align="center" rowspan="1" colspan="1">47</td><td valign="middle" align="center" rowspan="1" colspan="1">22</td><td valign="middle" rowspan="2" align="center" colspan="1">0.352</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;&#x0003c;3</td><td valign="middle" align="center" rowspan="1" colspan="1">34</td><td valign="middle" align="center" rowspan="1" colspan="1">20</td><td valign="middle" align="center" rowspan="1" colspan="1">14</td></tr><tr><td colspan="5" valign="middle" align="left" rowspan="1">Differentiation</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Well and moderate</td><td valign="middle" align="center" rowspan="1" colspan="1">57</td><td valign="middle" align="center" rowspan="1" colspan="1">40</td><td valign="middle" align="center" rowspan="1" colspan="1">17</td><td valign="middle" rowspan="2" align="center" colspan="1">0.224</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Poor</td><td valign="middle" align="center" rowspan="1" colspan="1">46</td><td valign="middle" align="center" rowspan="1" colspan="1">27</td><td valign="middle" align="center" rowspan="1" colspan="1">19</td></tr><tr><td colspan="5" valign="middle" align="left" rowspan="1">TNM stage</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;I/II</td><td valign="middle" align="center" rowspan="1" colspan="1">39</td><td valign="middle" align="center" rowspan="1" colspan="1">20</td><td valign="middle" align="center" rowspan="1" colspan="1">19</td><td valign="middle" rowspan="2" align="center" colspan="1">0.022<xref ref-type="table-fn" rid="tfn2-medscimonit-26-e924134">*</xref></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;III/IV</td><td valign="middle" align="center" rowspan="1" colspan="1">64</td><td valign="middle" align="center" rowspan="1" colspan="1">47</td><td valign="middle" align="center" rowspan="1" colspan="1">17</td></tr><tr><td colspan="5" valign="middle" align="left" rowspan="1">Lymph node metastasis</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td valign="middle" align="center" rowspan="1" colspan="1">67</td><td valign="middle" align="center" rowspan="1" colspan="1">49</td><td valign="middle" align="center" rowspan="1" colspan="1">18</td><td valign="middle" rowspan="2" align="center" colspan="1">0.019<xref ref-type="table-fn" rid="tfn2-medscimonit-26-e924134">*</xref></td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;No</td><td valign="middle" align="center" rowspan="1" colspan="1">36</td><td valign="middle" align="center" rowspan="1" colspan="1">18</td><td valign="middle" align="center" rowspan="1" colspan="1">18</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-medscimonit-26-e924134"><p>TNM &#x02013; tumor node metastasis.</p></fn><fn id="tfn2-medscimonit-26-e924134"><label>*</label><p><italic>P</italic>&#x0003c;0.05 represents statistical difference.</p></fn></table-wrap-foot></table-wrap></floats-group></article>